Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
34 studies found for:    " August 13, 2008":" September 12, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Active, not recruiting Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to Emtricitabine
Condition: HIV-1 Infection
Intervention: Drug: Emtricitabine
22 Completed TMC278-TiDP6-C121: Drug-drug Interaction Trial to Investigate the Potential Interaction Between TMC278 25 mg Daily and Methadone, at Steady State.
Condition: HIV
Intervention: Drug: TMC278
23 Completed
Has Results
A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen
Conditions: Virus Diseases;   HIV
Intervention: Drug: Switch NRTIs as a Backbone to Raltegravir
24 Unknown  Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment
Conditions: HIV;   AIDS;   Tuberculosis
Interventions: Drug: Simultaneous ARV and antiMTB;   Drug: Deferred RV and antiMTB treatment
25 Completed Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen
Condition: HIV
Intervention: Drug: Raltegravir
26 Completed TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women.
Conditions: HIV;   AIDS;   Oral Contraceptive
Intervention: Drug: TMC278
27 Completed TMC114-TiDP3-C181: Study to Assess the Pharmacokinetics of Darunavir (DRV) With Different Doses of Ritonavir in Healthy Volunteers.
Conditions: HIV;   AIDS
Intervention: Drug: Darunavir
28 Completed Assessment of Cytokine Values in Serum and by RT-PCR in HIV-1 Individuals With and Without HAART
Condition: HIV Infections
Intervention:
29 Unknown  Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment
Condition: HIV Infections
Intervention: Drug: Raltegravir and Atazanavir
30 Completed
Has Results
Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.
Conditions: HIV Infections;   HSV-2 Genital Herpes
Intervention: Drug: 3% SPL7013 Gel (VivaGel)
31 Completed Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults
Conditions: Cholera;   Vibrio Infections;   Diarrhea
Interventions: Biological: CholeraGarde®;   Biological: Placebo
32 Terminated
Has Results
Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)
Condition: Progressive Multifocal Leukoencephalopathy
Intervention: Drug: mefloquine
33 Completed Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial
Conditions: Brain and Central Nervous System Tumors;   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Other: educational intervention
34 Completed Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma
Conditions: Lung Cancer;   Lymphoma;   Lymphoproliferative Disorder;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: bevacizumab;   Drug: vandetanib;   Other: laboratory biomarker analysis;   Other: pharmacological study

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-34) Next Page   
Indicates status has not been verified in more than two years